we believe our focus on developing clinically useful tests that change patient care is enabling the company to set new standards in genomic test reimbursement . our flagship product , the afirma gec , is now covered for more than 200 million people in the u.s. for use in thyroid cancer diagnosis and our second commercial product , the percepta classifier , is the first genomic test to gain medicare coverage for improved lung cancer screening and diagnosis . fourth quarter and full-year 2016 financial results revenue for the three- and twelve-month periods ended december 31 , 2016 was $ 18.3 million and $ 65.1 million , respectively , an increase of 30 % and 31 % over the prior year . afirma gene expression classifier ( gec ) reported volume for the three- and twelve-month periods ended december 31 , 2016 was 6,313 and 23,237 , respectively , an increase of 13 % and 20 % over the prior year . operating expenses for the three- and twelve-month periods ended december 31 , 2016 , were $ 21.9 million and $ 93.9 million , respectively , an increase of 0 % and 13 % over the prior year . 43 net loss and comprehensive loss for the three- and twelve-month periods ended december 31 , 2016 was ( $ 4.4 ) million and ( $ 31.4 ) million , respectively , a 45 % and 7 % reduction from the prior year . cash and cash equivalents was $ 59.2 million at december 31 , 2016. during the twelve-month period ended december 31 , 2016 , the company raised $ 51.1 million in capital , including $ 19.2 million in net proceeds from its march 2016 debt financing and $ 31.9 million in net proceeds from a public offering of common stock . cash burn for the three- and twelve-month periods ended december 31 , 2016 ( which is defined as net cash used in operating activities and purchases of property and equipment ) , was $ 4.7 million and $ 32.2 million , respectively , a 33 % and 3 % improvement compared to the prior year . 2016 and recent business highlights reimbursement : executed a blues group-purchasing agreement in april 2016 , accelerating blues plan in-network contracting and overall reimbursement for the afirma gec thyroid cancer test . as of february 28 , 2017 , the company has more than 70 million blues plan members under coverage and nearly 25 million under contract . expanded overall covered lives for the afirma gec by 50 million to nearly 225 million and overall contracted lives by 25 million to over 155 million as of february 28 , 2017. achieved draft medicare coverage policies for the percepta bronchial genomic classifier for use in lung cancer screening and diagnosis , leading to two final policies scheduled to become effective in march 2017. clinical evidence and commercial expansion : clinical utility and cost-effectiveness data for the percepta classifier were presented at the american thoracic society and the chest annual meetings , further suggesting that use of the percepta classifier changes patient care and reduces healthcare costs as intended . launched the envisia genomic classifier at the chest annual meeting in october 2016 , in conjunction with the presentation of new data suggesting the test 's ability to significantly improve the diagnosis of ipf without the need for risky , expensive surgery . pipeline advancements : presented data at the american thyroid association meeting in september 2016 , demonstrating the potential for a next-generation afirma gec , planned for 2017 introduction , to substantially increase the percentage of patients with benign thyroid nodules who may be able to avoid unnecessary surgery . data were published in the journal of the national cancer institute suggesting the potential for the “ field of injury ” technology behind veracyte 's percepta classifier to enable lung cancer detection using a simple , non-invasive nasal swab test . factors affecting our performance the number of fnas we receive and gecs performed the growth in our business is tied to the number of fnas we receive and the number of gecs performed . approximately 84 % of fnas we receive are for the afirma solution , which consists of services related to rendering a cytopathology diagnosis , and if the cytopathology result is indeterminate , the gec is performed . the remaining approximate 16 % of fnas are received from customers performing cytopathology and when the cytopathology result is indeterminate , the fna is sent to us for the gec only . the rate at which adoption occurs in these two settings will cause these two percentages to fluctuate over time . less than 1 % of the fna samples we receive for cytopathology have insufficient cellular material from which to render a cytopathology 44 diagnosis . we only bill the technical component , including slide preparation , for these tests . for results that are benign or suspicious/malignant by cytopathology , we bill for these services when we issue the report to the physician . if the cytopathology result is indeterminate , defined as atypia/follicular lesions of undetermined significance ( aus/flus ) or suspicious for fn/hcn , we perform the gec . historically , approximately 14 % -17 % of samples we have received for the afirma solution have yielded indeterminate results by cytopathology . approximately 5 % -10 % of the samples for gec testing have insufficient rna from which to render a result . the gec can be reported as benign , suspicious or no result . we bill for the gec benign and gec suspicious results only . after the gec is completed , we issue the cytopathology report for the indeterminate results as well as the gec report , and then bill for both of these tests . story_separator_special_tag the preparation of the financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements , as well as the reported revenue generated and expenses incurred during the reporting periods . our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances , the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources . actual results may differ from these estimates under different assumptions or conditions and any such differences may be material . we believe that the accounting policies discussed below are critical to understanding our historical and future performance , as these policies relate to the more significant areas involving management 's judgments and estimates . revenue recognition we recognize revenue in accordance with the provisions of accounting standards codification ( “ asc ” ) 954-605 , health care entities — revenue recognition . our revenue is generated from the provision of diagnostic services . the service is completed upon the delivery of test results to the prescribing physician , at which time we bill for the service . we recognize revenue related to billings for tests delivered on an accrual basis when amounts that will ultimately be realized can be reasonably estimated . the estimates of amounts that will ultimately be realized require significant judgment by management . until a contract has been negotiated with a commercial payer or governmental program , our tests may or may not be covered by these entities ' existing reimbursement policies . in addition , patients do not enter into direct agreements with us that commit them to pay any portion of the cost of the tests in the event that their insurance declines to reimburse us . we may bill the patient directly for these amounts in the form of co-payments and co-insurance in accordance with their insurance carrier and health plans . in the absence of contracted reimbursement coverage or the ability to reasonably estimate the amount that will ultimately be realized for our services , revenue is recognized on the cash basis . we use judgment in determining if we are able to make a reasonable estimate of what will be ultimately realized . we also use judgment in estimating the amounts we expect to collect by payer . our judgments will continue to evolve in the future as we continue to gain payment experience . business combination we account for acquisitions using the acquisition method of accounting which requires the recognition of tangible and identifiable intangible assets acquired and liabilities assumed at their estimated fair values as of the business combination date . we allocate any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed to goodwill . transaction costs are expensed as incurred in general and administrative expenses . results of operations and cash flows of acquired companies are included in our operating results from the date of acquisition . finite-lived intangible assets finite-lived intangible assets relates to intangible assets reclassified from indefinite-lived intangible assets , following the launch of percepta in april 2015. we amortize finite-lived intangible assets using the straight-line method , over their estimated useful life . the estimated useful life of 15 years was used for the intangible asset related to percepta based on management 's estimate of product life , product life of other diagnostic tests and patent life . we test this finite-lived intangible asset for impairment when events or circumstances indicate a reduction in the fair value below its carrying amount . there was no impairment for the years ended december 31 , 2016 and 2015. goodwill goodwill , derived from our acquisition of allegro , is reviewed for impairment on an annual basis or more frequently if events or circumstances indicate that it may be impaired . our goodwill evaluation is based on both qualitative and quantitative assessments regarding the fair value of goodwill relative to its carrying value . we have determined that we operate in a single segment and have a single reporting unit associated with the development and commercialization of diagnostic products . in the event we determine that it is more likely than not the carrying value of the reporting unit is higher than its fair value , quantitative testing is performed comparing recorded values to estimated fair values . if impairment is present , the impairment loss is measured as the 49 excess of the recorded goodwill over its implied fair value . we perform our annual evaluation of goodwill during the fourth quarter of each fiscal year . there was no impairment for the years ended december 31 , 2016 and 2015 . stock-based compensation we recognize stock-based compensation expense for only those shares underlying stock options and restricted stock units that we expect to vest on a straight-line basis over the requisite service period of the award . we estimate the fair value of stock options using a black-scholes option-pricing model , which requires the input of highly subjective assumptions , including the option 's expected term and stock price volatility . in addition , judgment is also required in estimating the number of stock-based awards that are expected to be forfeited . forfeitures are estimated based on historical experience at the time of grant and revised , if necessary , in subsequent periods if actual forfeitures differ from those estimates . the assumptions used in calculating the fair value of share-based payment awards represent management 's best estimates , but these estimates involve inherent uncertainties and the application of management 's judgment . as a result , if factors change and we use different assumptions , our stock-based compensation expense could be materially different in the future . results of

cash flows from operating activities cash used in operating activities for the year ended december 31 , 2016 was $ 28.0 million . the net loss of $ 31.4 million includes non-cash charges of $ 0.9 million in amortization of the deferred fee received from genzyme , offset primarily by $ 6.4 million of stock-based compensation expense , $ 3.5 million of depreciation and amortization , which includes $ 1.1 million of intangible asset amortization , $ 0.4 million from conversion of accrued interest to long-term debt and $ 0.3 million in interest and prepayment penalty relating to the repayment of our borrowings under our 2013 loan agreement . cash used as a result of changes in operating assets and liabilities of $ 6.4 million is primarily due to an increase in accounts receivable of $ 5.3 million and a decrease in accounts payable of $ 1.4 million . cash used in operating activities for the year ended december 31 , 2015 was $ 27.0 million . the net loss of $ 33.7 million includes non-cash charges of $ 1.9 million in amortization of the deferred fee received from genzyme , offset primarily by $ 5.6 million of stock-based compensation expense , $ 2.3 million of depreciation and amortization , which includes $ 0.8 million intangible asset amortization following the launch of percepta in april 2015 , $ 0.1 million in amortization of debt discount and issuance costs and debt balloon interest expense , and $ 0.1 million of bad debt expense . the increase in net operating assets of $ 0.5 million was due to an increase of $ 0.9 million in deferred rent , accounts payable and accrued liabilities primarily from deferred rent from the lease for our new south san francisco facility , offset by $ 0.4 million from an increase in accounts receivable due to increases in afirma adoption and additional payers meeting our revenue recognition criteria for accrual .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```cash flows from operating activities cash used in operating activities for the year ended december 31 , 2016 was $ 28.0 million . the net loss of $ 31.4 million includes non-cash charges of $ 0.9 million in amortization of the deferred fee received from genzyme , offset primarily by $ 6.4 million of stock-based compensation expense , $ 3.5 million of depreciation and amortization , which includes $ 1.1 million of intangible asset amortization , $ 0.4 million from conversion of accrued interest to long-term debt and $ 0.3 million in interest and prepayment penalty relating to the repayment of our borrowings under our 2013 loan agreement . cash used as a result of changes in operating assets and liabilities of $ 6.4 million is primarily due to an increase in accounts receivable of $ 5.3 million and a decrease in accounts payable of $ 1.4 million . cash used in operating activities for the year ended december 31 , 2015 was $ 27.0 million . the net loss of $ 33.7 million includes non-cash charges of $ 1.9 million in amortization of the deferred fee received from genzyme , offset primarily by $ 5.6 million of stock-based compensation expense , $ 2.3 million of depreciation and amortization , which includes $ 0.8 million intangible asset amortization following the launch of percepta in april 2015 , $ 0.1 million in amortization of debt discount and issuance costs and debt balloon interest expense , and $ 0.1 million of bad debt expense . the increase in net operating assets of $ 0.5 million was due to an increase of $ 0.9 million in deferred rent , accounts payable and accrued liabilities primarily from deferred rent from the lease for our new south san francisco facility , offset by $ 0.4 million from an increase in accounts receivable due to increases in afirma adoption and additional payers meeting our revenue recognition criteria for accrual .
```    
 Suspicious Activity Report : we believe our focus on developing clinically useful tests that change patient care is enabling the company to set new standards in genomic test reimbursement . our flagship product , the afirma gec , is now covered for more than 200 million people in the u.s. for use in thyroid cancer diagnosis and our second commercial product , the percepta classifier , is the first genomic test to gain medicare coverage for improved lung cancer screening and diagnosis . fourth quarter and full-year 2016 financial results revenue for the three- and twelve-month periods ended december 31 , 2016 was $ 18.3 million and $ 65.1 million , respectively , an increase of 30 % and 31 % over the prior year . afirma gene expression classifier ( gec ) reported volume for the three- and twelve-month periods ended december 31 , 2016 was 6,313 and 23,237 , respectively , an increase of 13 % and 20 % over the prior year . operating expenses for the three- and twelve-month periods ended december 31 , 2016 , were $ 21.9 million and $ 93.9 million , respectively , an increase of 0 % and 13 % over the prior year . 43 net loss and comprehensive loss for the three- and twelve-month periods ended december 31 , 2016 was ( $ 4.4 ) million and ( $ 31.4 ) million , respectively , a 45 % and 7 % reduction from the prior year . cash and cash equivalents was $ 59.2 million at december 31 , 2016. during the twelve-month period ended december 31 , 2016 , the company raised $ 51.1 million in capital , including $ 19.2 million in net proceeds from its march 2016 debt financing and $ 31.9 million in net proceeds from a public offering of common stock . cash burn for the three- and twelve-month periods ended december 31 , 2016 ( which is defined as net cash used in operating activities and purchases of property and equipment ) , was $ 4.7 million and $ 32.2 million , respectively , a 33 % and 3 % improvement compared to the prior year . 2016 and recent business highlights reimbursement : executed a blues group-purchasing agreement in april 2016 , accelerating blues plan in-network contracting and overall reimbursement for the afirma gec thyroid cancer test . as of february 28 , 2017 , the company has more than 70 million blues plan members under coverage and nearly 25 million under contract . expanded overall covered lives for the afirma gec by 50 million to nearly 225 million and overall contracted lives by 25 million to over 155 million as of february 28 , 2017. achieved draft medicare coverage policies for the percepta bronchial genomic classifier for use in lung cancer screening and diagnosis , leading to two final policies scheduled to become effective in march 2017. clinical evidence and commercial expansion : clinical utility and cost-effectiveness data for the percepta classifier were presented at the american thoracic society and the chest annual meetings , further suggesting that use of the percepta classifier changes patient care and reduces healthcare costs as intended . launched the envisia genomic classifier at the chest annual meeting in october 2016 , in conjunction with the presentation of new data suggesting the test 's ability to significantly improve the diagnosis of ipf without the need for risky , expensive surgery . pipeline advancements : presented data at the american thyroid association meeting in september 2016 , demonstrating the potential for a next-generation afirma gec , planned for 2017 introduction , to substantially increase the percentage of patients with benign thyroid nodules who may be able to avoid unnecessary surgery . data were published in the journal of the national cancer institute suggesting the potential for the “ field of injury ” technology behind veracyte 's percepta classifier to enable lung cancer detection using a simple , non-invasive nasal swab test . factors affecting our performance the number of fnas we receive and gecs performed the growth in our business is tied to the number of fnas we receive and the number of gecs performed . approximately 84 % of fnas we receive are for the afirma solution , which consists of services related to rendering a cytopathology diagnosis , and if the cytopathology result is indeterminate , the gec is performed . the remaining approximate 16 % of fnas are received from customers performing cytopathology and when the cytopathology result is indeterminate , the fna is sent to us for the gec only . the rate at which adoption occurs in these two settings will cause these two percentages to fluctuate over time . less than 1 % of the fna samples we receive for cytopathology have insufficient cellular material from which to render a cytopathology 44 diagnosis . we only bill the technical component , including slide preparation , for these tests . for results that are benign or suspicious/malignant by cytopathology , we bill for these services when we issue the report to the physician . if the cytopathology result is indeterminate , defined as atypia/follicular lesions of undetermined significance ( aus/flus ) or suspicious for fn/hcn , we perform the gec . historically , approximately 14 % -17 % of samples we have received for the afirma solution have yielded indeterminate results by cytopathology . approximately 5 % -10 % of the samples for gec testing have insufficient rna from which to render a result . the gec can be reported as benign , suspicious or no result . we bill for the gec benign and gec suspicious results only . after the gec is completed , we issue the cytopathology report for the indeterminate results as well as the gec report , and then bill for both of these tests . story_separator_special_tag the preparation of the financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements , as well as the reported revenue generated and expenses incurred during the reporting periods . our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances , the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources . actual results may differ from these estimates under different assumptions or conditions and any such differences may be material . we believe that the accounting policies discussed below are critical to understanding our historical and future performance , as these policies relate to the more significant areas involving management 's judgments and estimates . revenue recognition we recognize revenue in accordance with the provisions of accounting standards codification ( “ asc ” ) 954-605 , health care entities — revenue recognition . our revenue is generated from the provision of diagnostic services . the service is completed upon the delivery of test results to the prescribing physician , at which time we bill for the service . we recognize revenue related to billings for tests delivered on an accrual basis when amounts that will ultimately be realized can be reasonably estimated . the estimates of amounts that will ultimately be realized require significant judgment by management . until a contract has been negotiated with a commercial payer or governmental program , our tests may or may not be covered by these entities ' existing reimbursement policies . in addition , patients do not enter into direct agreements with us that commit them to pay any portion of the cost of the tests in the event that their insurance declines to reimburse us . we may bill the patient directly for these amounts in the form of co-payments and co-insurance in accordance with their insurance carrier and health plans . in the absence of contracted reimbursement coverage or the ability to reasonably estimate the amount that will ultimately be realized for our services , revenue is recognized on the cash basis . we use judgment in determining if we are able to make a reasonable estimate of what will be ultimately realized . we also use judgment in estimating the amounts we expect to collect by payer . our judgments will continue to evolve in the future as we continue to gain payment experience . business combination we account for acquisitions using the acquisition method of accounting which requires the recognition of tangible and identifiable intangible assets acquired and liabilities assumed at their estimated fair values as of the business combination date . we allocate any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed to goodwill . transaction costs are expensed as incurred in general and administrative expenses . results of operations and cash flows of acquired companies are included in our operating results from the date of acquisition . finite-lived intangible assets finite-lived intangible assets relates to intangible assets reclassified from indefinite-lived intangible assets , following the launch of percepta in april 2015. we amortize finite-lived intangible assets using the straight-line method , over their estimated useful life . the estimated useful life of 15 years was used for the intangible asset related to percepta based on management 's estimate of product life , product life of other diagnostic tests and patent life . we test this finite-lived intangible asset for impairment when events or circumstances indicate a reduction in the fair value below its carrying amount . there was no impairment for the years ended december 31 , 2016 and 2015. goodwill goodwill , derived from our acquisition of allegro , is reviewed for impairment on an annual basis or more frequently if events or circumstances indicate that it may be impaired . our goodwill evaluation is based on both qualitative and quantitative assessments regarding the fair value of goodwill relative to its carrying value . we have determined that we operate in a single segment and have a single reporting unit associated with the development and commercialization of diagnostic products . in the event we determine that it is more likely than not the carrying value of the reporting unit is higher than its fair value , quantitative testing is performed comparing recorded values to estimated fair values . if impairment is present , the impairment loss is measured as the 49 excess of the recorded goodwill over its implied fair value . we perform our annual evaluation of goodwill during the fourth quarter of each fiscal year . there was no impairment for the years ended december 31 , 2016 and 2015 . stock-based compensation we recognize stock-based compensation expense for only those shares underlying stock options and restricted stock units that we expect to vest on a straight-line basis over the requisite service period of the award . we estimate the fair value of stock options using a black-scholes option-pricing model , which requires the input of highly subjective assumptions , including the option 's expected term and stock price volatility . in addition , judgment is also required in estimating the number of stock-based awards that are expected to be forfeited . forfeitures are estimated based on historical experience at the time of grant and revised , if necessary , in subsequent periods if actual forfeitures differ from those estimates . the assumptions used in calculating the fair value of share-based payment awards represent management 's best estimates , but these estimates involve inherent uncertainties and the application of management 's judgment . as a result , if factors change and we use different assumptions , our stock-based compensation expense could be materially different in the future . results of

